Stem Cell Reports

Stem Cell Reports (commonly abbreviated as Stem Cell Rep.) is the official journal of the International Society for Stem Cell Research, published by Cell Press, an imprint of Elsevier. Established in 2013 and issued monthly, it has been fully open access from the outset and publishes original research in stem cell biology and regenerative medicine, serving as a principal publishing route in the field without a subscription barrier.《干细胞报告》（Stem Cell Reports，常用缩写为 Stem Cell Rep.）是国际干细胞研究学会的会刊，由爱思唯尔旗下 Cell Press 出版，2013 年创刊，月刊发行。该刊自创刊起即完全开放获取，刊载干细胞生物学与再生医学的原创研究，是这一领域不设订阅门槛的主要发表渠道之一。

Scope

The journal takes as its editorial stance an even balance between fundamental discovery in stem cell biology and clinical translation toward regenerative medicine, publishing both mechanistic work on pluripotency and reprogramming and applied studies leading to organoids, disease models and cell therapies, and requiring that papers advance understanding of stem cell behaviour rather than merely describe it. Its principal subject areas include:本刊的取稿立场是让「干细胞生物学的基础发现」与「向再生医学的临床转化」两端并重，既收多能性调控与重编程的机制研究，也收以类器官、疾病模型与细胞治疗为出口的应用工作，并明确要求论文须推进对干细胞行为的理解，而非仅作现象描述。收文覆盖的主要方向包括：

• Pluripotency and reprogramming: induced pluripotency, somatic cell reprogramming, and the regulatory mechanisms of epigenetic and transcriptional networks.多能性与重编程： 诱导多能性、体细胞重编程、表观遗传与转录网络的调控机制。
• Adult stem cells and regeneration: self-renewal, differentiation and tissue repair in haematopoietic, neural, muscle and epithelial stem cells.成体干细胞与再生： 造血、神经、肌肉与上皮干细胞的自我更新、分化与组织修复。
• Organoids and in vitro models: organoid construction, disease modelling, gene-editing screens and high-throughput functional genomics.类器官与体外模型： 类器官构建、疾病建模、基因编辑筛选与高通量功能基因组学。
• Niche and immune regulation: the stem cell niche, the extracellular matrix, and the interplay of inflammatory responses with immune cells.微环境与免疫调控： 干细胞龛、细胞外基质、炎症反应与免疫细胞的相互作用。
• Translation and clinical research: preclinical evaluation, cell therapy product development, and the ethical, regulatory and standards questions raised by stem cell research.转化与临床研究： 临床前评价、细胞治疗产品开发，以及干细胞研究的伦理、监管与标准议题。

The journal also carries reviews, perspectives and policy pieces addressing the ethics, regulation and standards of stem cell research, while research articles and short reports remain its principal article types. Neither the society nor the publisher publishes an acceptance rate, and the only official timeline given is a median of 178 days from submission to acceptance, a figure that spans both editorial screening and external peer review.期刊另设评述、观点与政策类稿件，用以讨论干细胞研究的伦理、监管与标准议题；研究论文与短篇报告仍是最主要的稿件类型。学会与出版方均不公布本刊的录用比例，官方仅公布投稿至录用的中位时间为 178 天，该口径涵盖编辑部初筛与外部同行评审两个阶段。

History

• Founding context (2013): the journal was proposed by Haifan Lin, then president of the International Society for Stem Cell Research, took about three years to prepare, and published its first issue in June 2013 ahead of that year's annual meeting in Boston. The founding editor was Christine Mummery of Leiden University Medical Center.创刊背景（2013年）： 本刊由时任国际干细胞研究学会会长林海帆（Haifan Lin）提议创办，筹备历时约三年，2013 年 6 月出版首期，赶在当年学会波士顿年会前上线；创刊主编为莱顿大学医学中心的克里斯蒂娜·穆梅里（Christine Mummery）。^[1]
• First-issue submissions: the inaugural editorial disclosed that the editorial office received close to one hundred manuscripts in the less than six months following its first open call in December 2012, showing how strongly the society's backing pulled in submissions.首期稿源： 首期社论披露，编辑部自 2012 年 12 月首次公开征稿起不到半年即收到近一百篇稿件，学会背书对稿源的拉动作用由此可见。^[2]
• Open access from the outset: the society decided at the project stage to publish on a fully open access basis, with authors retaining copyright and a choice between the CC BY 4.0 and CC BY-NC-ND 4.0 licences. The publisher's current article processing charge is US$4,400, reduced by 13 per cent for society members and by a further half for corresponding authors who join for the first time.开放获取取向： 学会自立项起即决定以完全开放获取方式出版，作者保留版权，许可可在 CC BY 4.0 与 CC BY-NC-ND 4.0 之间选择；出版方现行文章处理费为 4400 美元，学会会员减收 13%，首次入会的通讯作者另可再减半。^[3]
• Editorial succession: the founding editor Mummery served until 2018, followed by Martin F. Pera of The Jackson Laboratory, who held the post from early 2019 through the end of 2024, and Janet Rossant of the University of Toronto, who took over from January 2025.主编更替： 创刊主编穆梅里任职至 2018 年，其后由杰克逊实验室的马丁·佩拉（Martin F. Pera）接任并于 2019 年初至 2024 年底在任，2025 年 1 月起由多伦多大学的珍妮特·罗桑特（Janet Rossant）接掌。^[4]
• Publisher and serial numbers: the journal is published by Elsevier under the Cell Press imprint, the serial number authority recording the place of publication as Amsterdam in the Netherlands. It has been electronic-only since launch, carrying the single online serial number 2213-6711 and no separate print number.出版方与刊号： 期刊由爱思唯尔以 Cell Press 品牌出版，权威刊号记录将其出版地著录为荷兰阿姆斯特丹；本刊自创刊起即为纯电子刊，只有电子刊号 2213-6711，没有独立的印刷版刊号。^[5]
• Policies and milestones: the journal was among the earlier Cell Press titles to promise explicit scoop protection, under which the editors will not reject a paper for lack of novelty if a similar result is published elsewhere while it is under review or revision. By its tenth anniversary in 2023 it had published close to two thousand papers.栏目与传播里程碑： 本刊是 Cell Press 系列中较早明确承诺「抢先保护」的刊物，即审稿或修回期间若有他人发表相似成果，编辑部不以新颖性不足为由退稿；2023 年十周年时累计发表已接近两千篇。^[6]
• Metric trend: the impact factor eased from 7.765 in 2020 to 5.6 in 2025, fluctuating between 5.1 and 5.9 in the interim. In the 2025 Chinese Academy of Sciences ranking it sits in the medical class 1 zone overall, with cell and tissue engineering and cell biology both at zone 2.指标走势： 影响因子自 2020 年的 7.765 回落至 2025 年的 5.6，期间在 5.1 至 5.9 之间波动；2025 年在中科院分区中列于医学大类一区，小类细胞与组织工程、细胞生物学均为二区。^[7]

Editors

The journal operates under a peer review framework led by an editor-in-chief, with associate editors overseeing separate subject areas and an honorary board in support. Manuscripts are submitted through the Editorial Manager system and may enter Cell Press's multi-journal submission arrangement, under which one manuscript can be considered by several titles in the family at once. The editorial team is drawn from research centres across Europe, North America and Asia, giving it a broadly balanced international composition.本刊实行主编统筹、副编辑分领域把关、另设荣誉编委的同行评审架构；稿件经 Editorial Manager 系统投递，并可参与 Cell Press 的多刊联合投送机制，即一篇稿件可同时由系列内多个刊物考虑。编辑部成员来自欧洲、北美与亚洲多个研究中心，构成较为均衡的国际布局。

• Janet Rossant (editor-in-chief since 2025): professor emeritus in the Department of Molecular Genetics at the University of Toronto and senior scientist emeritus at the SickKids Research Institute, a fellow of the Royal Society and of the Royal Society of Canada, long active in mouse early development and stem cell research, and previously president of the Gairdner Foundation in Canada.珍妮特·罗桑特（2025年起任）： 多伦多大学分子遗传系荣休教授、SickKids 研究院荣休资深科学家，英国皇家学会与加拿大皇家学会会士，长期从事小鼠早期发育与干细胞研究，此前曾主持加拿大盖尔德纳基金会。^[8]
• Martin F. Pera (2019–2024): then a professor at The Jackson Laboratory, he served six years as editor-in-chief, a period in which the journal settled into a stable monthly schedule and joined the Cell Press multi-journal submission arrangement.马丁·佩拉（2019–2024）： 时任杰克逊实验室教授，任主编六年，任内刊物完成从季刊到月刊的稳定化编排并进入 Cell Press 联合投送机制。^[8]
• Christine Mummery (2013–2018): the founding editor and a professor at Leiden University Medical Center, whose work concerns the differentiation of pluripotent stem cells toward cardiac and vascular lineages, and who is among the representative figures of European stem cell research.克里斯蒂娜·穆梅里（2013–2018）： 首任主编，莱顿大学医学中心教授，研究方向为多能干细胞向心肌与血管谱系的分化，是欧洲干细胞研究的代表性学者之一。^[8]
• Associate editors: the current team includes Patrick Cahan of Johns Hopkins University, Ludovic Vallier of the Berlin Institute of Health and Hongmei Wang of the Institute of Zoology, Chinese Academy of Sciences, covering gene-editing screens, disease modelling and reproductive development.副编辑团队： 现行编辑团队包括约翰斯·霍普金斯大学的帕特里克·卡汉（Patrick Cahan）、柏林健康研究所的吕多维克·瓦利耶（Ludovic Vallier）与中国科学院动物研究所的王红梅等，覆盖基因编辑筛选、疾病建模与生殖发育等方向。^[8]
• Standing in the field: a broadly influential open access journal in stem cell research, its papers routinely serving as base citations for later reviews and clinical protocols in the field, with a stable citation volume when set beside the society titles of Europe and North America.学科地位： 本刊是干细胞研究领域影响广泛的开放获取刊物，其论文常成为该方向后续综述与临床方案的基础引用来源，在与欧洲、北美多个学会刊的并置中保持着稳定的引用体量。^[7]